#Canada #Aurora Cannabis #Edmonton #medical cannabis #Miguel Martin

Aurora Cannabis Annual General Meeting Outcomes

On August 10, 2026, Aurora Cannabis Inc., a top-tier player in the global medical cannabis industry, conducted its Annual General Meeting (AGM) via a virtual platform. This gathering was pivotal for stakeholders eager to gauge the company’s direction and governance, pivotal elements in reinforcing the firm’s commitment to transparency and shareholder engagement.

The AGM recorded a significant turnout with 16,639,306 shares represented, accounting for 26.86% of the total common shares in circulation. Aurora’s governance has entered a new phase of growth and confidence, reflected in the voting results for the Board of Directors and other key resolutions brought to the table.

Voting Results and Director Confirmation

The results from the directors' vote illustrated a solid endorsement of the leadership team:

• - Miguel Martin: 5,076,096 votes for (85.12%), 887,633 votes withheld
• - Michael Singer: 5,148,795 votes for (86.34%), 814,934 votes withheld
• - Chitwant Kohli: 5,134,736 votes for (86.10%), 828,993 votes withheld
• - Norma Beauchamp: 5,159,834 votes for (86.52%), 803,895 votes withheld
• - Rajesh Uttamchandani: 5,127,871 votes for (85.98%), 835,857 votes withheld

The shareholder approval also extended to the appointment of Ernst Young LLP as the auditors for the upcoming year and the endorsement of the executive compensation plan, with 82.97% of shareholders voting in favor.

Statements from Leadership

In response to the meeting's outcomes, Miguel Martin, the Executive Chairman and CEO, expressed his contentment with the positive reception from shareholders. He stated, "We appreciate the support received at this year’s meeting. This confidence in our Board of Directors allows us to maintain focus on executing our medical-first strategy and strengthening our global cannabis operations, ensuring long-term value for our shareholders."

Looking Forward

Aurora Cannabis remains dedicated to reinforcing its global presence within the medical cannabis sector, driven by its commitment to quality and patient care. The company continues to operate across significant markets in Canada, Europe, Australia, and New Zealand, backed by a robust portfolio featuring well-recognized brands such as Aurora®, MedReleaf®, and IndiMed™. As they look to the future, their aim is not only to expand but also to set benchmarks in industry standards by focusing on high-quality production backed by their state-of-the-art, GMP-certified manufacturing facilities in both Canada and Germany.

In light of their recent decisions and strategic directions, Aurora is poised to navigate through evolving market dynamics effectively. As they gear up for the coming year, the main objective remains clear: deliver consistent, high-quality cannabis products while continuing to innovate within their operational frameworks. Stakeholders and customers can look forward to seeing how these strategies unfold, as Aurora Cannabis commits to its vision of Opening the World to Cannabis™.

For additional insights and details about Aurora, visit their official website at www.auroramj.com and stay connected through their social media channels on X and LinkedIn.